Advances in genome editing have transformed the development of animal models used to understand human diseases. While transgenic mouse models have broadly ...
Q3 2025 Earnings Call Transcript November 4, 2025 OmniAb, Inc. misses on earnings expectations. Reported EPS is $-0.14 EPS, ...
More research into crop variety development is using gene editing. Canada’s regulatory approach to gene editing will help ...
Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced ...
Modern genetics reveals that over 50 genes across many chromosomes—not just X and Y—govern sex development. The term “sex ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for ...
Origin Agritech Ltd. (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology ...
OmniAb Inc (OABI) showcases robust program growth and strategic advancements despite facing revenue challenges in Q3 2025.
Chroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced new preclinical data presented at The Liver ...
OmniAb provided detailed guidance for the remainder of 2025, projecting revenue between $18-$22 million and operating expenses of $82-$86 million. The company anticipates ending the year with a cash ...
The Daily Galaxy on MSN
Scientists Used a Tardigrade’s Superpower to Create a ‘Superworm’ That Defies Time, Stress, and Radiation
A protein unique to tardigrades—microscopic invertebrates famous for surviving boiling, freezing, and space vacuum—has now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback